Matinas BioPharma Holdings, Inc. announced receipt of written feedback from U.S. Food and Drug Administration (FDA) on its proposed revised protocol for a Phase 3 study of MAT2203 in patients with invasive aspergillosis with limited or no treatment options. The preliminary written comments move the Company closer to alignment with the FDA on the design of a single Phase 3 registration trial for the approval of MAT2203. At the FDA's invitation, the Company is planning a meeting early in the first quarter of 2024 to discuss and finalize the Phase 3 protocol and position MAT2203 to commence Phase 3 as soon as possible thereafter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1789 USD | -1.43% | -4.69% | -17.25% |
Mar. 27 | Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024 | |
Mar. 27 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.25% | 44.87M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MTNB Stock
- News Matinas BioPharma Holdings, Inc.
- Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA